Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful

Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.

CNBC Television • Oct 23, 2026

Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall

Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day.

CNBC • Oct 23, 2026

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn't stopped. Those numbers landed short of the loftiest hopes built into a long rally.

24/7 Wall Street • Oct 23, 2026

Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

Investors Business Daily • Oct 23, 2026

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

When a drugmaker's top product loses patent protection, the dividend usually takes the hit.

24/7 Wall Street • Oct 23, 2026

Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2026

Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data

Moderna shares are taking a hit after the leak of highly anticipated details about the company's vaccine for the skin cancer melanoma.

Investopedia • Oct 22, 2026

Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story.

24/7 Wall Street • Oct 22, 2026

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in c.

Business Wire • Oct 22, 2026

Merck (MRK) Laps the Stock Market: Here's Why

The latest trading day saw Merck (MRK) settling at $149.88, representing a +1.07% change from its previous close.

Zacks Investment Research • Oct 21, 2026